Overview
ROXRO PHARMA, Inc. is a privately owned, virtually organized specialty pharmaceutical company focused on developing innovative treatments for pain.
Founded in 1999, ROXRO was one of the first pharmaceutical start-ups built upon the “virtual company” business model. Led by a highly experienced senior management team, ROXRO has assembled a global network of external experts to successfully bring its products through all aspects of development.
ROXRO Pharma's mission is to develop innovative treatments for acute pain, focusing on convenient, non-invasive solutions that improve patient outcomes. The company aims to address gaps in pain management by repurposing or further developing compounds that have been deprioritized by larger pharmaceutical firms. By focusing on underutilized molecules, ROXRO seeks to offer new therapeutic options for patients while leveraging cost-effective drug development strategies.
ROXRO Pharma's first product was, an intranasal formulation of ketorolac, a non-steroidal anti-inflammatory treatment. The same molecular was aimed to offer an effective, non-opioid option for patients, minimizing the side effects and dependency risks associated with narcotic pain relievers for managing acute pain, particularly in post-surgical settings.
Building on this success, the company has focused on developing new treatments designed to alleviate pain for patients undergoing surgeries and addressing pain management across multiple diseases. This ongoing work aligns with ROXRO's mission to innovate and improve the quality of life for patients by offering more accessible and less painful treatment options